Payers

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

A Blood Test Will Not Fix Colorectal Screening by Itself

Alzheimer’s Treatment Moves Home. Risk Does Not.

Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing

Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge

New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly

Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore

Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems

Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
